Turn recording back on
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
Pillai SK, Wong JK, Barbour JD.
Retrovirology. 2008 Mar 13;5:26.
PMID: 18339206 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z, Zhang W, Chen G, Xu R, Yu XF.
J Mol Biol. 2008 Sep 12;381(4):1000-11. Epub 2008 Jun 28.
PMID: 18619467 [PubMed - indexed for MEDLINE]
Related Articles
Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
Izumi T, Shirakawa K, Takaori-Kondo A.
Mini Rev Med Chem. 2008 Mar;8(3):231-8. Review.
PMID: 18336343 [PubMed - indexed for MEDLINE]
HIV-1 Vif, APOBEC, and intrinsic immunity.
Goila-Gaur R, Strebel K.
Retrovirology. 2008 Jun 24;5:51. Review.
PMID: 18577210 [PubMed - indexed for MEDLINE]
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA, Pathak VK.
J Virol. 2007 Aug;81(15):8201-10. Epub 2007 May 23.
PMID: 17522216 [PubMed - indexed for MEDLINE]
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK.
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7. Epub 2004 Mar 30.
PMID: 15054139 [PubMed - indexed for MEDLINE]
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y, Wang X, Dang Y, Zheng YH.
PLoS Pathog. 2008 Jul 4;4(7):e1000095.
PMID: 18604271 [PubMed - indexed for MEDLINE]
Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
Marin M, Golem S, Rose KM, Kozak SL, Kabat D.
J Virol. 2008 Jan;82(2):987-98. Epub 2007 Oct 31.
PMID: 17977970 [PubMed - indexed for MEDLINE]
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D.
J Virol. 2007 Dec;81(23):13235-41. Epub 2007 Sep 26.
PMID: 17898068 [PubMed - indexed for MEDLINE]
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM.
J Virol. 2004 Jun;78(11):6073-6.
PMID: 15141007 [PubMed - indexed for MEDLINE]
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D.
J Biol Chem. 2004 Feb 27;279(9):7792-8. Epub 2003 Dec 13.
PMID: 14672928 [PubMed - indexed for MEDLINE]
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
Dang Y, Wang X, Esselman WJ, Zheng YH.
J Virol. 2006 Nov;80(21):10522-33. Epub 2006 Aug 18.
PMID: 16920826 [PubMed - indexed for MEDLINE]
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT, Brown WL, Schumacher AJ, Harris RS.
Curr Biol. 2004 Aug 10;14(15):1385-91.
PMID: 15296757 [PubMed - indexed for MEDLINE]
[Antiviral defense by APOBEC3 family proteins]
Takaori A.
Uirusu. 2005 Dec;55(2):267-72. Review. Japanese.
PMID: 16557012 [PubMed - indexed for MEDLINE]
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF.
J Virol. 2006 Mar;80(6):3112-5.
PMID: 16501124 [PubMed - indexed for MEDLINE]
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Schröfelbauer B, Senger T, Manning G, Landau NR.
J Virol. 2006 Jun;80(12):5984-91.
PMID: 16731937 [PubMed - indexed for MEDLINE]
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK, Koning FA, Bishop KN, Malim MH.
J Biol Chem. 2007 Jan 26;282(4):2587-95. Epub 2006 Nov 22.
PMID: 17121840 [PubMed - indexed for MEDLINE]
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S.
J Virol. 2006 Sep;80(18):9259-69. Erratum in: J Virol. 2007 Aug;81(16):8843-5.
PMID: 16940537 [PubMed - indexed for MEDLINE]
Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.
Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA.
J Virol. 2008 Aug;82(16):8172-82. Epub 2008 Jun 11.
PMID: 18550667 [PubMed - indexed for MEDLINE]
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
Haché G, Shindo K, Albin JS, Harris RS.
Curr Biol. 2008 Jun 3;18(11):819-24. Epub 2008 May 22.
PMID: 18501607 [PubMed - indexed for MEDLINE]